SARS-CoV-2感染与疫苗接种住院皮肤科医生的皮肤表现

IF 2.4 Q2 DERMATOLOGY

Current Dermatology Reports Pub Date : 2022-01-01 DOI:10.1007/s13671-022-00374-5

Sonia Himed, Ashley Gray, Zaynah Awethe, Karissa Libson, Benjamin H Kaffenberger, Abraham M Korman, John C L Trinidad

{"title":"SARS-CoV-2感染与疫苗接种住院皮肤科医生的皮肤表现","authors":"Sonia Himed, Ashley Gray, Zaynah Awethe, Karissa Libson, Benjamin H Kaffenberger, Abraham M Korman, John C L Trinidad","doi":"10.1007/s13671-022-00374-5","DOIUrl":null,"url":null,"abstract":"Purpose of review: The overall purpose of this review was to characterize and summarize cutaneous eruptions associated with coronavirus disease 2019 (COVID-19) as well as COVID-19 vaccination.Recent findings: Cutaneous eruptions associated with COVID-19 infection have a reported frequency of 1-20%. Increased COVID-19 disease severity has been associated with morbilliform exanthems, urticaria, retiform purpura, and livedo racemosa. Papulovesicular eruptions were associated with a milder COVID-19 disease course. A range of dermatoses have also been reported with COVID-19 vaccination but have rarely prevented subsequent vaccination.Summary: Dermatologists should be aware of the associations between COVID-19 disease severity and cutaneous eruptions. Livedo racemosa and retiform purpura are particularly associated with increased disease severity and death. In the setting of COVID-19 vaccination, cutaneous eruptions can largely be managed symptomatically and very rarely do these reactions prevent subsequent vaccination.","PeriodicalId":10838,"journal":{"name":"Current Dermatology Reports","volume":"11 4","pages":"252-262"},"PeriodicalIF":2.4000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9579541/pdf/","citationCount":"0","resultStr":"{\"title\":\"SARS-CoV-2 Infection and Vaccination Cutaneous Manifestations for the Inpatient Dermatologist.\",\"authors\":\"Sonia Himed, Ashley Gray, Zaynah Awethe, Karissa Libson, Benjamin H Kaffenberger, Abraham M Korman, John C L Trinidad\",\"doi\":\"10.1007/s13671-022-00374-5\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Purpose of review: The overall purpose of this review was to characterize and summarize cutaneous eruptions associated with coronavirus disease 2019 (COVID-19) as well as COVID-19 vaccination.Recent findings: Cutaneous eruptions associated with COVID-19 infection have a reported frequency of 1-20%. Increased COVID-19 disease severity has been associated with morbilliform exanthems, urticaria, retiform purpura, and livedo racemosa. Papulovesicular eruptions were associated with a milder COVID-19 disease course. A range of dermatoses have also been reported with COVID-19 vaccination but have rarely prevented subsequent vaccination.Summary: Dermatologists should be aware of the associations between COVID-19 disease severity and cutaneous eruptions. Livedo racemosa and retiform purpura are particularly associated with increased disease severity and death. In the setting of COVID-19 vaccination, cutaneous eruptions can largely be managed symptomatically and very rarely do these reactions prevent subsequent vaccination.\",\"PeriodicalId\":10838,\"journal\":{\"name\":\"Current Dermatology Reports\",\"volume\":\"11 4\",\"pages\":\"252-262\"},\"PeriodicalIF\":2.4000,\"publicationDate\":\"2022-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9579541/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current Dermatology Reports\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1007/s13671-022-00374-5\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"DERMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Dermatology Reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s13671-022-00374-5","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"DERMATOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

综述目的:本综述的总体目的是描述和总结与2019冠状病毒病(COVID-19)相关的皮肤皮疹以及COVID-19疫苗接种。最近发现:据报道，与COVID-19感染相关的皮肤皮疹发生率为1-20%。增加的COVID-19疾病严重程度与麻疹样疹、荨麻疹、网状紫癜和活状红斑有关。丘疹水疱性爆发与较轻的COVID-19病程相关。据报道，在接种COVID-19疫苗后也出现了一系列皮肤病，但很少阻止后续接种。总结:皮肤科医生应该意识到COVID-19疾病严重程度与皮肤爆发之间的关联。总形紫癜和网状紫癜尤其与疾病严重程度和死亡增加有关。在接种COVID-19疫苗的情况下，皮肤皮疹基本上可以对症处理，这些反应很少妨碍后续的疫苗接种。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

SARS-CoV-2 Infection and Vaccination Cutaneous Manifestations for the Inpatient Dermatologist.

Purpose of review: The overall purpose of this review was to characterize and summarize cutaneous eruptions associated with coronavirus disease 2019 (COVID-19) as well as COVID-19 vaccination.

Recent findings: Cutaneous eruptions associated with COVID-19 infection have a reported frequency of 1-20%. Increased COVID-19 disease severity has been associated with morbilliform exanthems, urticaria, retiform purpura, and livedo racemosa. Papulovesicular eruptions were associated with a milder COVID-19 disease course. A range of dermatoses have also been reported with COVID-19 vaccination but have rarely prevented subsequent vaccination.

Summary: Dermatologists should be aware of the associations between COVID-19 disease severity and cutaneous eruptions. Livedo racemosa and retiform purpura are particularly associated with increased disease severity and death. In the setting of COVID-19 vaccination, cutaneous eruptions can largely be managed symptomatically and very rarely do these reactions prevent subsequent vaccination.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Current Dermatology Reports DERMATOLOGY-

CiteScore

3.30

自引率

6.20%

发文量

期刊介绍： This journal intends to review the most significant recent developments in the field of dermatology. By providing clear, insightful, balanced contributions by expert international authors, the journal aims to serve all those involved in the diagnosis, treatment, management, and prevention of dermatologic conditions. We accomplish this aim by appointing international authorities to serve as Section Editors in key subject areas across the field, such as epidemiology, surgery, pharmacology, clinical trial design, and pediatrics. Section Editors select topics for which leading experts contribute comprehensive review articles that emphasize new developments and recently published papers of major importance, highlighted by annotated reference lists. We also provide commentaries from well-known figures in the field, and an Editorial Board of more than 20 internationally diverse members suggests topics of special interest to their country/region and ensures that topics are current and include emerging research.